AEGiS-AP: Roche Laments AIDS Drug Delivery Associated PressImportant note: Information in this article was accurate in 2001. The state of the art may have changed since the publication date.
Click here to return to Associated Press main menu




DonateNow



Roche Laments AIDS Drug Delivery

Associated Press - Friday October 5, 2001


BASEL, Switzerland (AP) - With AIDS drug prices slashed for the poorest countries, the problem now is how to get the vital medicine delivered to people with the disease, the head of Swiss pharmaceutical giant Roche said Friday.

"We need infrastructure, training ... political will and commitment," Roche chief executive Franz Humer told Dow Jones Newswires.

"We're committed to playing a part in fighting AIDS and for that purpose we're supplying our drugs at no profit or free of charge, but I think people understand the issue is no longer price," he said.

Pharmaceutical companies have begun to cut prices after coming under fire for charging amounts beyond the reach of most poor countries.

AIDS campaigners also accused the companies of blocking the efforts by some countries to produce generic versions of the drugs, often at much lower prices.

Drugs companies, for their part, have warned that research and development on AIDS and HIV drugs could slow or stop if patent rights are unprotected.

Humer met Thursday with U.N. Secretary-General Kofi Annan and officials from six other drugs companies for talks on improving access to AIDS drugs.

Measures discussed included reducing drug prices, improving health services and encouraging private sector involvement, Humer said.

He said the discussions also included encouraging partnership between local government groups, U.N. agencies and the pharmaceutical industry.

Large drug companies are not the only members of the private sector expected to play their part, he said.

"Major employers in afflicted countries should also allocate resources to promote prevention," Humer said.

Approximately 36 million people worldwide have HIV, the virus that lead to AIDS, according to the United Nation's AIDS agency, UNAIDS.
011005
AP011003


Copyright © 2001 - Associated Press. Reproduction of this article (other than one copy for personal reference) must be cleared through the AP Permissions Desk.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Broadway Cares/Equity Fights AIDS, Elton John AIDS Foundation, National Library of Medicine, Pacific Life Foundation, and donations from users like you.

Always watch for outdated information. This article first appeared in 2001. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 2001. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .